These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038 [TBL] [Abstract][Full Text] [Related]
44. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143 [TBL] [Abstract][Full Text] [Related]
45. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma. Alchami FS; Attanoos RL; Bamber AR J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081 [TBL] [Abstract][Full Text] [Related]
46. The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation. Kinoshita T; Ishii G; Matsumura Y; Shiozawa T; Aokage K; Hishida T; Yoshida J; Nagai K Pathol Int; 2012 Nov; 62(11):754-7. PubMed ID: 23121607 [TBL] [Abstract][Full Text] [Related]
47. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. Bovolato P; Casadio C; Billè A; Ardissone F; Santambrogio L; Ratto GB; Garofalo G; Bedini AV; Garassino M; Porcu L; Torri V; Pastorino U J Thorac Oncol; 2014 Mar; 9(3):390-6. PubMed ID: 24518090 [TBL] [Abstract][Full Text] [Related]
48. Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database. Abdel-Rahman O Strahlenther Onkol; 2017 Apr; 193(4):276-284. PubMed ID: 28044200 [TBL] [Abstract][Full Text] [Related]
49. National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma. Verma V; Ahern CA; Berlind CG; Lindsay WD; Sharma S; Shabason J; Culligan MJ; Grover S; Friedberg JS; Simone CB J Thorac Oncol; 2017 Nov; 12(11):1704-1714. PubMed ID: 28843362 [TBL] [Abstract][Full Text] [Related]
50. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative. Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894 [TBL] [Abstract][Full Text] [Related]
51. Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma. Yang CJ; Yan BW; Meyerhoff RR; Saud SM; Gulack BC; Speicher PJ; Hartwig MG; D'Amico TA; Harpole DH; Berry MF Clin Lung Cancer; 2016 Sep; 17(5):419-426. PubMed ID: 27236386 [TBL] [Abstract][Full Text] [Related]
52. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review. Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120 [TBL] [Abstract][Full Text] [Related]
53. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216 [TBL] [Abstract][Full Text] [Related]
55. Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study. Marulli G; Breda C; Fontana P; Ratto GB; Leoncini G; Alloisio M; Infante M; Luzzi L; Paladini P; Oliaro A; Ruffini E; Benvenuti MR; Pariscenti G; Spaggiari L; Casiraghi M; Rusca M; Carbognani P; Ampollini L; Facciolo F; Leuzzi G; Mucilli F; Camplese P; Romanello P; Perissinotto E; Rea F Eur J Cardiothorac Surg; 2017 Jul; 52(1):63-69. PubMed ID: 28419212 [TBL] [Abstract][Full Text] [Related]
56. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients. Taioli E; Wolf AS; Camacho-Rivera M; Kaufman A; Lee DS; Nicastri D; Rosenzweig K; Flores RM PLoS One; 2015; 10(12):e0145039. PubMed ID: 26660351 [TBL] [Abstract][Full Text] [Related]
57. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897 [TBL] [Abstract][Full Text] [Related]
58. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study. de Boer NL; van Kooten JP; Damhuis RAM; Aerts JGJV; Verhoef C; Madsen EVE Ann Surg Oncol; 2019 Dec; 26(13):4222-4228. PubMed ID: 31620941 [TBL] [Abstract][Full Text] [Related]
59. The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma. Lewis GD; Dalwadi SM; Farach A; Brian Butler E; Teh BS Ann Surg Oncol; 2019 Jun; 26(6):1879-1885. PubMed ID: 30798447 [TBL] [Abstract][Full Text] [Related]